

Amendments to the Specification

On page 1, please amend the paragraph starting on line 4 as follows:

The present application is a U.S. National Phase Application of International Application PCT/US2002/036283, filed November 13, 2002, which ~~This application~~ claims the benefit of priority from U.S. Provisional Application No. 60/331,231 of the same title filed Nov. November 13, 2001, the entire disclosure disclosures of which are hereby is incorporated by reference in its entirety their entireties.

On page 6, please amend the paragraph starting on line 17 as follows:

In another embodiment, the invention provides a pharmaceutical composition comprising an effective amount of a polypeptide sequence of selected from the group consisting of SEQ ID NO 1, SEQ ID NO 2, biologically active fragments thereof, and variants thereof, and a pharmaceutically acceptable carrier. ~~The composition of claim 5, wherein~~ In one embodiment, the composition is a therapeutic or post-exposure prophylactic. Preferably, the composition is in the form of a vaccine.